Cervical cancer during pregnancy linked to higher maternal health risks

A new research paper was published in Oncoscience's Volume 12 on January 20, 2025, titled "Maternal, delivery and neonatal outcomes in women with cervical cancer. A study of a population database."

In this large study, researchers Aaron Samuels, Ahmad Badeghiesh, Haitham Baghlaf, and Michael H. Dahan – from McGill University, King Abdulaziz University, University of Tabuk, and McGill University Health Center – found that pregnant women diagnosed with cervical cancer face higher risks of health problems during pregnancy and childbirth. However, these health risks do not seem to affect the health of their babies.

Cervical cancer is one of the most common cancers among women worldwide and is often linked to human papillomavirus (HPV) infection. While the impact of cervical cancer on women's health is well known, there has been limited research on how it affects pregnancy outcomes. To better understand this, the researchers analyzed data from over nine million pregnancies in the United States between 2004 and 2014. Among these cases, 222 women were diagnosed with cervical cancer before giving birth.

The study found that pregnant women with cervical cancer were more likely to be older than 35, smoke, use illicit drugs, and have chronic high blood pressure compared to those without the disease. When it came to childbirth, these women were nearly five times more likely to give birth prematurely and to require a cesarean section. They also faced an alarmingly high risk of needing a hysterectomy, a surgical procedure to remove the uterus, compared to women without cervical cancer. Additionally, the risk of developing dangerous blood clots, such as deep vein thrombosis or pulmonary embolism, was significantly higher in this group.

Despite these serious health risks for mothers, the study found no major differences in the health of the babies. Rates of birth defects, stillbirths, and low birth weight were similar between mothers with cervical cancer and those without. 

"Cervical cancer during pregnancy is associated with significant maternal and delivery risks, however, neonatal outcomes are largely unaffected."

These findings highlight the importance of specialized care for pregnant women diagnosed with cervical cancer, as effective management requires a multidisciplinary team specializing in oncological, obstetrical, and neonatal care. 

"Preconception counseling should address co-morbidities and prior medical treatments to optimize outcomes. Timely follow-up and prompt treatment during pregnancy remain critical."

As more women choose to have children later in life, this research offers critical guidance for healthcare providers and reassurance for expectant mothers facing a cervical cancer diagnosis. It also highlights the need for further studies to understand the long-term health outcomes for children born to mothers with cervical cancer, as well as the potential effects of cancer treatments during pregnancy.

Source:
Journal reference:

Samuels, A., et al. (2025). Maternal, delivery and neonatal outcomes in women with cervical cancer. A study of a population database. Oncoscience. doi.org/10.18632/oncoscience.613.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop T cell growth method that enhances cancer-fighting ability in melanoma model